Phage Therapy - Part A, Volume 200 is an informative text on phage and their use for treatment in bacterial infections. The book highlights a number of aspects of the phage in a way that can help students, researchers, clinicians, entrepreneurs and stakeholders perform their research with great interest. Chapters in this new release cover An introduction to bacteriophage and their therapeutic applications, Isolation, screening and characterization of phage, Synthetic phage and their application in phage therapy, Phage engineering for development of diagnostic tools, Phage design and directed evolution to evolve phage for therapy, and more. Additional sections cover Host-phage interactions and modelling for therapy, Phage and phage cocktails formulations, Phage for treatment of Escherichia coli infection, Phage for treatment of Klebsiella pneumoniae infection, Phage for treatment of Salmonella spp infection, Phage for treatment of Staphylococcus aureus infection, and Phages for treatment of Acinetobacter baumannii infection. - Includes discussions on phage isolation, screening and characterization - Covers synthetic phage, phage for diagnostic, directed evolution and host interaction - Presents the latest on phage for treatment of bacterial infections

This book gives a detailed yet clear insight into the current state of the art of the therapeutic application of bacteriophages in different conditions. The authors bring in their practical expertise within their respective fields of expertise and provide an excellent overview of the potential and actual use of phage therapy. Topics like economic feasibility compared to traditional antibiotics and also regulatory issues are discussed in far detail. This new volume is therefore a valuable resource for individuals engaged in the medical application of novel phage therapies.

Phage Therapy - Part A, Volume 200 is an informative text on phage and their use for treatment in bacterial infections. The book highlights a number of aspects of the phage in a way that can help students, researchers, clinicians, entrepreneurs and stakeholders perform their research with great interest. Chapters in this new release cover An introduction to bacteriophage and their therapeutic applications, Isolation, screening and characterization of phage, Synthetic phage and their application in phage therapy, Phage engineering for development of diagnostic tools, Phage design and directed evolution to evolve phage for therapy, and more. Additional sections cover Host-phage interactions and modelling for therapy, Phage and phage cocktails formulations, Phage for treatment of Escherichia coli infection, Phage for treatment of Klebsiella pneumoniae infection, Phage for treatment of Salmonella spp infection, Phage for treatment of Staphylococcus aureus infection, and Phages for treatment of Acinetobacter baumannii infection.

Phage Therapy - Part B, Volume 201 covers bacteriophage and their isolation, screening, synthetic phage, diagnostics, directed evolution, host interaction, and more. The book's aim is to highlight a number of aspects of phage in a way that can help students, researchers, clinicians, entrepreneurs and stakeholders perform research. Sections cover Phages for the treatment of Pseudomonas aeruginosa infection, Phage for the treatment of Vibrio cholerae infection, Phages for the treatment of Mycobacterium species, Phage therapy for gut microbiome, Phages as delivery vehicles, Phage display, Unlocking the potential of Phages: Innovative Approaches to harnessing Bacteriophages as Diagnostic Tools for Human Diseases, and more. Other sections explore Phage display and human disease detection, Bacteriophage as Cargo and its application in nanomedicine, Phage for drug delivery vehicles, Genome editing for phage design and uses for therapeutic applications, Phage for cancer therapy, and Phage for regenerative medicine and cosmetics. - Includes sections on phage isolation, screening and characterization - Covers synthetic phage, phage for diagnostic, directed evolution, and host interaction - Explores Phage for the treatment of bacterial infections

This book fills a void. Never before has a comprehensive history of phage therapy—a once-neglected, now resurgent field—been written. Kuchment writes from the perspective of the eager student of history for the common reader.

This volume details the experimental approaches suitable for isolating and characterizing bacteriophages to formulating bacteriophage medicinal products and clinical application. Chapters guide readers through regulatory compliance and safety aspects of bacteriophage therapy. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and cutting-edge, Bacteriophage Therapy: From Lab to Clinical Practice aims to ensure successful results in the further study of this vital field.

This volume is an essential reference for anyone interested in phage therapy and a highly recommended book for everyone working in the areas of antibacterial resistance, antimicrobial development, bacteriophage research, biocontrol and biodetection.

This first major reference work dedicated to the mannifold industrial and medical applications of bacteriophages provides both theoretical and practical insights into the emerging field of bacteriophage biotechnology. The book introduces to bacteriophage biology, ecology and history and reviews the latest technologies and tools in bacteriophage detection, strain optimization and nanotechnology. Usage of bacteriophages in food safety, agriculture, and different therapeutic areas is discussed in detail. This book serves as essential guide for researchers in applied microbiology, biotechnology and medicine coming from both academia and industry.

Fighting Multidrug Resistance with Herbal Extracts, Essential Oils and their Components offers scientists a single source aimed at fighting specific multidrug-resistant (MDR) microorganisms such as bacteria, protozoans, viruses and fungi using natural products. This essential reference discusses herbal extracts and essential oils used or under investigation to treat MDR infections, as well as those containing antimicrobial activity that could be of potential interest in future studies against MDR microorganisms. The need to combat multidrug-resistant microorganisms is an urgent one and this book provides important coverage of mechanism of action, the advantages and disadvantages of using herbal extracts, essential oils and their components and more to aid researchers in effective antimicrobial drug discovery - Addresses the need to develop safe and effective approaches to coping with resistance to all classes of antimicrobial drugs - Provides readers with current evidence-based content aimed at using herbal extracts and essential oils in antimicrobial drug development - Includes chapters devoted to the activity of herbal products against herpes, AIDS, tuberculosis, drug-resistant cancer cells and more

This Research Topic is dedicated to Prof. Elisabeth Kutter on the occasion of her 80th birthday. Dr. Kutter’s career as a phage scientist has extended nearly 60 years. She has been a pioneer as a woman in science. She started to work with phage at the University of Rochester, New York working with Dr. Wiberg on radioisotopes making excellent progress in the field – progress which was even cited in Luria’s 1969 Nobel Prize talk. Betty first encountered phage therapy during a visit to Georgia in 1990 which was part of a longer stay in the former Soviet Union under a US-USSR research exchange program. Dr. Kutter was one of the first Americans to advocate for phage therapy in the post antibiotic era. Betty started hosting the Evergreen International Phage meetings in Olympia, Washington, from 1975 onward, which helped to develop a strong phage community with participation increasing over the years to 350 at the 23 rd biannual last year. Betty continues to be an active member in the phage community, sharing her experience and working with all of us toward her ultimate goal of making phage therapy available worldwide thus reducing the burden caused by antibiotic resistant bacterial infections.